13010-47-4 Usage
Chemical Properties
Lomustine is a pale yellow powder.
Uses
Different sources of media describe the Uses of 13010-47-4 differently. You can refer to the following data:
1. CCNU is an oral anticancer drug that was approved by the U.S. Food and Drug Administration in 1976 for marketing, as lomustine (FDA 2009a). CCNU is used alone or in combination with other antineoplastic agents, including procarbazine and vincristine, etoposide and prednimustine, and other combinations (IARC 1981, HSDB 2009). It is used primarily in the treatment of Hodgkin’s disease and brain tumors, but it has also been used to treat other cancer, includ-ing lung cancer, non-Hodgkin’s lymphoma, malignant melanoma, breast cancer, kidney cancer, and cancer of the gastrointestinal tract (MedlinePlus 2009). It has also been applied to the skin to treat mycosis fungoides and psoriasis.
2. Lomustine USP is used to treat Malignant brain tumors; Hodgkin’s disease.
3. Chloroethylnitrosourea derivative with antitumor activity. Similar to carmustine, chlorozotocin, nimustine, ranimustine. Antineoplastic.
Definition
ChEBI: An N-nitrosourea that is urea in which one of the nitrogens is substituted by a 2-chloroethyl group and by a nitroso group, while the other nitrogen is substituted by a cyclohexyl group. An alkylating antineoplastic agent, it is used in
he treatment of brain tumours, lung cancer, malignant melanoma and other solid tumours.
Brand name
Ceenu (Bristol-Myers
Squibb).
Synthesis Reference(s)
Journal of Medicinal Chemistry, 18, p. 104, 1975 DOI: 10.1021/jm00235a023Synthesis, p. 1027, 1987 DOI: 10.1055/s-1987-28160
General Description
Lomustine is available in 10-, 40-, and 100-mg capsules fororal administration in the treatment of primary and metastaticbrain cancers and Hodgkin’s lymphoma. This lipophilicagent is well absorbed, widely distributed, and crosses theblood-brain barrier. Lomustine undergoes extensive hepaticmetabolism, which is mediated by CYP3A4 to give severalhydroxylated metabolites, which arise as a result of oxidationof the cyclohexyl ring. Several of these are more activethan the parent compound. Denitrosation and dechlorinationhave also been demonstrated to occur for lomustine as well.The intact drug was not found in plasma when the agent wasadministered orally. Elimination occurs primarily in theurine with an elimination half-life of 16 to 72 hours.Myelosuppression is dose limiting and presents in a mannersimilar to that seen with carmustine. Other toxicities includenausea, vomiting, anorexia, impotence, sterility, amenorrhea,and infertility. Pulmonary and renal toxicity are rarelyseen during standard-dose therapy but increase during highdosetherapy.
Biological Activity
lomustine is an antineoplastic drug used in chemotherapy [1]lomustine has been revealed to inhibit the growth of tumour cell lines with ic50 values of 25μm, 8.8μm and 13μm for breast zr-75-1, astrocytoma u87mg and colorectal ls174t cell lines [2]. besides, lomustine has been found to be particularly effective in the treatment of certain neoplasms of the central nervous system, because of the high lipid solubility and permeability through the blood brain barrier. in addition, lomustine has shown the effect function in treatment of meningeal leukemia in the mouse and in children who have acute leukemia with central nervous system involvement [1].
Biochem/physiol Actions
Antineoplastic agent with cellular DNA effects. Lomustine induces p53 expression in A2870 cells.
Mechanism of action
Like other nitrosoureas, lomustine acts as a DNA-alkylating agent, and it also inhibits various key enzymatic reactions by carbamoylating proteins.
Clinical Use
#N/A
Safety Profile
Confirmed carcinogen
with experimental carcinogenic and
tumorigenic data. Poison by ingestion,
intraperitoneal, subcutaneous, intravenous,
and possibly other routes. Human systemic
effects by ingestion: anorexia, nausea or
vomiting, leukopenia (decrease in the white
blood cell count), and thrombocytopenia
(decrease in the number of blood platelets).
Experimental teratogenic and reproductive
effects. Human mutation data reported.
When heated to decomposition it emits very
toxic fumes of Cland NOx. See also NNITROSO COMPOUNDS.
Synthesis
Lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (30.2.4.3), is made
by reacting ethanolamine with cyclohexylisocyanate, which forms 1-(2-hydroxyethyl)-3-
cyclohexylurea (30.2.4.1). Upon reaction with thionyl chloride, the hydroxyl group in it is
replaced with a chlorine atom, giving 1-(2-chloroethyl)-3-cyclohexylurea (30.2.4.2). This
is nitrated in non-aqueous conditions with formic acid and sodium nitrite to give lomustine (30.2.4.3).
Potential Exposure
A potential danger to those involved
in the manufacture, administration or consumption of this
antineoplastic (anti-cancer) agent
Veterinary Drugs and Treatments
Lomustine may be useful in the adjunctive treatment of CNS neoplasms,
lymphomas, and mast cell tumors in dogs and cats.
Carcinogenicity
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) is reasonably
anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.
Metabolism
Molecular weight (daltons) 233.7
% Protein binding 60
% Excreted unchanged in urine 50 (as metabolites)
Volume of distribution (L/kg) No data
Half-life - normal/ESRF (hrs) 16-48 (metabolites)
Waste Disposal
It is inappropriate and possibly
dangerous to the environment to dispose of expired or waste
drugs and pharmaceuticals by flushing them down the toilet
or discarding them to the trash. Household quantities of
expired or waste pharmaceuticals may be mixed with wet
cat litter or coffee grounds, double-bagged in plastic, discard
in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper
disposal being careful to properly label and securely package
the material. Alternatively, the waste pharmaceutical shall be
labeled, securely packaged and transported by a state
licensed medical waste contractor to dispose by burial in a
licensed hazardous or toxic waste landfill or incinerator.
references
[1] cheng cj, fujimura s, grunberger d, weinstein ib. nteraction of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (nsc 79037) with nucleic acids and proteins in vivo and in vitro. cancer res. 1972 jan;32(1):22-7.[2] baer jc1, freeman aa, newlands es, watson aj, rafferty ja, margison gp. depletion of o6-alkylguanine-dna alkyltransferase correlates with potentiation of temozolomide and ccnu toxicity in human tumour cells.br j cancer. 1993 jun; 67(6):1299-302.
Check Digit Verification of cas no
The CAS Registry Mumber 13010-47-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,0,1 and 0 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 13010-47:
(7*1)+(6*3)+(5*0)+(4*1)+(3*0)+(2*4)+(1*7)=44
44 % 10 = 4
So 13010-47-4 is a valid CAS Registry Number.
InChI:InChI=1/C9H16ClN3O2/c1-2-12(10)9(14)13(11-15)8-6-4-3-5-7-8/h8H,2-7H2,1H3
13010-47-4Relevant articles and documents
Tin(IV) chloride-sodium nitrite as a new nitrosating agent for N-nitrosation of amines, amides and ureas under mild and heterogeneous conditions
Celaries, Benoit,Parkanyi, Cyril
, p. 2371 - 2375 (2006)
We have developed a new method of N-nitrosation of various secondary and tertiary amines, amides and ureas using a mixture of tin(IV) chloride and sodium nitrate. This method leads to a selective, high-yielding and mild heterogeneous N-nitrosation by in situ generation of nitrosyl chloride (NOCl). The reaction can be carried out in several different solvents such as chloroform, dichloromethane, ethers, ethyl acetate and alcohols, at room temperature. Georg Thieme Verlag Stuttgart.
Johnston et al.
, p. 104,105 (1975)
Concatamers for Immunemodulation
-
, (2012/04/23)
The invention relates to a polymeric, non-coding nucleic acid molecule for modulation of the activity of the human and animal immune system as well as a method for the manufacture thereof and a vaccine, comprising the polymeric, non-coding nucleic acid molecule, wherein polymeric, non-coding nucleic acid molecules may be understood as non-coding nucleic acid molecules, comprising at least four covalently bound molecules (tetramer) or are assemblies of more non-coding nucleic acid molecules (high molecular polymers) which are covalently bound to each other.
Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
-
, (2010/05/13)
Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.
